Sendas Distribuidora (ASAI3) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
19 Nov, 2025Executive summary
Gross revenue reached BRL 20.3 billion in Q1 2025, up 7.8% year-over-year, with same-store sales growth of 5.5% and new store maturation contributing to results.
Achieved highest EBITDA margin since 1Q21 at 5.5%, driven by operational efficiency and expense control.
Net income pre-adjustments was BRL 162 million (+74.2%), with post-adjustments at BRL 117 million (+95.0%).
Recognized as the 92nd largest global retailer and top-ranked Brazilian company in Deloitte's 2025 ranking.
Focused on cash generation, deleveraging, and maintaining a balance between growth and financial health.
Financial highlights
Adjusted EBITDA pre-IFRS16 reached BRL 1.0 billion, margin up 0.3 p.p. year-over-year to 5.5%.
Net income increased by 74% year-over-year, with significant improvement in both pre- and post-vision metrics.
Free cash flow generation totaled BRL 1.6 billion over the last twelve months.
Net debt reduced from BRL 13.8 billion to BRL 13.4 billion, and net debt/EBITDA ratio improved to 3.15x.
Cash and cash equivalents totaled BRL 6.0 billion, up 17% from 1Q24.
Outlook and guidance
Expansion plan for 2025 and 2026 targets approximately 10 new store openings per year, with some projects postponed due to higher capital costs and interest rates.
Guidance to reach a net debt/EBITDA ratio of 2.6x by end of 2025, with CAPEX between BRL 1.0–1.2 billion.
Focus remains on organic growth, with M&A considered but not prioritized under current macroeconomic conditions.
Latest events from Sendas Distribuidora
- Revenue up 5.2%, EBITDA margin 5.8%, leverage 2.56x, and free cash flow R$2.8B.ASAI3
Q4 202512 Feb 2026 - Revenue and EBITDA rose as leverage improved, with over 300 stores targeted for 2024.ASAI3
Q2 20241 Feb 2026 - Revenue and EBITDA up, leverage down, and expansion and deleveraging remain priorities.ASAI3
Q3 202415 Jan 2026 - Board size cut, compensation reduced, and new poison pill triggers reflect governance reforms.ASAI3
Status Update26 Dec 2025 - Record revenue, margin gains, and lower leverage defined 2024's strong performance.ASAI3
Q4 202411 Dec 2025 - Revenue up 7.2% and net income up 60% year-over-year, with strong cash flow and lower leverage.ASAI3
Q2 202523 Nov 2025 - Revenue, EBITDA margin, and free cash flow rose as leverage hit a multi-year low.ASAI3
Q3 202513 Nov 2025